Impact Associated With Pertuzumab and Trastuzumab SC and IV Formulations Utilization in Metastatic HER2-Positive Breast Cancer Patients Treated in Brazilian SUS

OBJECTIVES: Estimate resource use associated with subcutaneous (SC) fixed-dose combination of P+T (PT SC) and as intravenous formulation pertuzumab and trastuzumab (P+T IV) formulations in metastatic breast cancer (mBC) HER2-positive (HER2+) patients treatment in Brazilian Public System (SUS)

METHODS: Healthcare resource utilization (HRU) data with each formulation was collected from experts interviews. For each alternative, preparation, administration and monitoring times and costs were considered based on official sources. Time spent by patients, healthcare professionals (HCPs) and associated costs were estimated for a 5-year period based on DataSUS data of patients currently treated and projection for the 2024-2028 horizon.

RESULTS: In 1-year period (18 cycles), considering administration and chair times and costs with HCPs, P+T IV and PT SC treatment resulted in BRL 1,457 and BRL 170 per patient, respectively. On average, PT SC allows savings of 32.2 hours/patient vs IV. Time savings with PT SC would allow to treat 5 times more HER2+ mBC patients requiring 1-year treatment in SUS vs P+T IV. Considering 75,599 mBC HER2+ patients projected to require treatment at SUS in 2024-2028 period, PT SC adoption would result in Public savings of BRL 97,345,134 (BRL 110,199,112 vs BRL 12,853,977 with P+T IV and PT SC, respectively)

CONCLUSIONS: Considering HRU, using SC vs IV formulations could save Brazilian SUS more than 97 million BRL in a 5 year period, ease hospital burden by reducing HCP required time and patients stays at hospital, increasing their quality of life and potentiate more patients being treated in due time.